{"id":30668,"date":"2022-06-15T23:39:00","date_gmt":"2022-06-15T15:39:00","guid":{"rendered":"https:\/\/flcube.com\/?p=30668"},"modified":"2025-03-26T23:41:26","modified_gmt":"2025-03-26T15:41:26","slug":"china-nt-pharma-group-company-ltd-inks-licensing-deal-for-monoclonal-antibodies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30668","title":{"rendered":"China NT Pharma Group Company Ltd Inks Licensing Deal for Monoclonal Antibodies"},"content":{"rendered":"\n<p>China-based China NT Pharma Group Company Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/1011:HKG\">HKG: 1011<\/a>) has announced a potential acquisition agreement with an undisclosed US firm. Under the terms of the agreement, its wholly owned subsidiary, Green-Life Technology (Hong Kong) Co., Ltd, will obtain exclusive and permanent commercial licensing rights to several monoclonal antibodies (mAbs) for Greater China (including mainland China, Hong Kong, Macau, and Taiwan), Singapore, Malaysia, and Thailand. The technology, currently at the Phase II trial stage, is being developed to treat multiple diseases.<\/p>\n\n\n\n<p><strong>Licensing and Cooperation Agreement<\/strong><br>One of the prerequisites of the licensing and cooperation agreement is the establishment of a consultancy agreement between NT Pharma, the licensee, and the consultant. As part of the deal, NT Pharma shall allot and issue new shares to the consultant as consideration for providing consultancy services for the commercialization of certain monoclonal antibody products. The consultant will lead the research and development of the technology and is responsible for submitting the clinical application of the technology to the relevant regulatory bodies.<\/p>\n\n\n\n<p><strong>Joint Venture Framework<\/strong><br>NT Pharma entered into a framework agreement with the municipal government to set up a joint venture (JV) in April this year. The JV, expected to become a subsidiary of NT Pharma, will be a comprehensive biotech company focused on research and development, manufacturing, marketing, and services. However, as of the announcement date, NT Pharma has not signed any formal agreements related to the acquisition, sales, or establishment of the JV.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based China NT Pharma Group Company Ltd (HKG: 1011) has announced a potential acquisition agreement&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2133,2134],"class_list":["post-30668","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-1011","tag-nt-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China NT Pharma Group Company Ltd Inks Licensing Deal for Monoclonal Antibodies - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based China NT Pharma Group Company Ltd (HKG: 1011) has announced a potential acquisition agreement with an undisclosed US firm. Under the terms of the agreement, its wholly owned subsidiary, Green-Life Technology (Hong Kong) Co., Ltd, will obtain exclusive and permanent commercial licensing rights to several monoclonal antibodies (mAbs) for Greater China (including mainland China, Hong Kong, Macau, and Taiwan), Singapore, Malaysia, and Thailand. The technology, currently at the Phase II trial stage, is being developed to treat multiple diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30668\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China NT Pharma Group Company Ltd Inks Licensing Deal for Monoclonal Antibodies\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30668\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-15T15:39:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-26T15:41:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30668#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30668\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China NT Pharma Group Company Ltd Inks Licensing Deal for Monoclonal Antibodies\",\"datePublished\":\"2022-06-15T15:39:00+00:00\",\"dateModified\":\"2025-03-26T15:41:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30668\"},\"wordCount\":255,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 1011\",\"NT Pharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30668#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30668\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30668\",\"name\":\"China NT Pharma Group Company Ltd Inks Licensing Deal for Monoclonal Antibodies - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-06-15T15:39:00+00:00\",\"dateModified\":\"2025-03-26T15:41:26+00:00\",\"description\":\"China-based China NT Pharma Group Company Ltd (HKG: 1011) has announced a potential acquisition agreement with an undisclosed US firm. Under the terms of the agreement, its wholly owned subsidiary, Green-Life Technology (Hong Kong) Co., Ltd, will obtain exclusive and permanent commercial licensing rights to several monoclonal antibodies (mAbs) for Greater China (including mainland China, Hong Kong, Macau, and Taiwan), Singapore, Malaysia, and Thailand. The technology, currently at the Phase II trial stage, is being developed to treat multiple diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30668#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30668\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30668#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China NT Pharma Group Company Ltd Inks Licensing Deal for Monoclonal Antibodies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China NT Pharma Group Company Ltd Inks Licensing Deal for Monoclonal Antibodies - Insight, China&#039;s Pharmaceutical Industry","description":"China-based China NT Pharma Group Company Ltd (HKG: 1011) has announced a potential acquisition agreement with an undisclosed US firm. Under the terms of the agreement, its wholly owned subsidiary, Green-Life Technology (Hong Kong) Co., Ltd, will obtain exclusive and permanent commercial licensing rights to several monoclonal antibodies (mAbs) for Greater China (including mainland China, Hong Kong, Macau, and Taiwan), Singapore, Malaysia, and Thailand. The technology, currently at the Phase II trial stage, is being developed to treat multiple diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30668","og_locale":"en_US","og_type":"article","og_title":"China NT Pharma Group Company Ltd Inks Licensing Deal for Monoclonal Antibodies","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=30668","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-06-15T15:39:00+00:00","article_modified_time":"2025-03-26T15:41:26+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30668#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30668"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China NT Pharma Group Company Ltd Inks Licensing Deal for Monoclonal Antibodies","datePublished":"2022-06-15T15:39:00+00:00","dateModified":"2025-03-26T15:41:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30668"},"wordCount":255,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 1011","NT Pharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30668#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30668","url":"https:\/\/flcube.com\/?p=30668","name":"China NT Pharma Group Company Ltd Inks Licensing Deal for Monoclonal Antibodies - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-06-15T15:39:00+00:00","dateModified":"2025-03-26T15:41:26+00:00","description":"China-based China NT Pharma Group Company Ltd (HKG: 1011) has announced a potential acquisition agreement with an undisclosed US firm. Under the terms of the agreement, its wholly owned subsidiary, Green-Life Technology (Hong Kong) Co., Ltd, will obtain exclusive and permanent commercial licensing rights to several monoclonal antibodies (mAbs) for Greater China (including mainland China, Hong Kong, Macau, and Taiwan), Singapore, Malaysia, and Thailand. The technology, currently at the Phase II trial stage, is being developed to treat multiple diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30668#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30668"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30668#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China NT Pharma Group Company Ltd Inks Licensing Deal for Monoclonal Antibodies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30668","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30668"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30668\/revisions"}],"predecessor-version":[{"id":30669,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30668\/revisions\/30669"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30668"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30668"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}